Development consulting and affairs group PharmaLex has teamed up with privately held Volv Global to bolster its pharmacovigilance business.
The project will see the duo use artificial intelligence (AI) technology, such as Volv’s predictive technologies, unassisted machine learning, paradigms and web-scale technologies, to develop products and services for PharmaLex’s clients.
Dr Thomas Dobmeyer, chief executive officer of PharmaLex, said: “The increasing volume of relevant literature in the medico-scientific domain is a challenge.
“Embedded artificial intelligence and cognitive computing technology allows for increased efficiency, especially in the area of drug adverse even monitoring.
Initially focusing on pharmacovigilance services, the project will centre in on supporting and monitoring adverse events that recorded on web forums and social media channels, regulatory intelligence platforms, patient identification for rare diseases and related services.
Christopher Rudolf, founder and chief executive officer of Volv Global, said: “We are delighted to be working with PharmaLex on the development of their pharmacovigilance (PV) solutions.
“Our innovative technology has an open design and intuitive interface, ensuring it can easily integrate into existing PV platforms.”